Discovery & Development

A partnership between Gilead Sciences and Georgia State University has tested a new oral antiviral for COVID-19.

Two members of the Drugs for Neglected Diseases initiative lay out how they improved access to Hep C treatment in Southeast Asia and beyond.

How will vaccine and therapeutic makers respond to the new SARS-CoV-2 variant?

Exploring the potential of vaccines for treatment equity.

How can the NLRP3 inflammasome can be exploited to slow the decline associated with Alzheimer's disease?

A drug development journey with origins in the 1950s has finally reached its successful conclusion: a new treatment for lupus.

Jan Cools of the VIB Center for Cancer Biology discusses his experience with Mission Bio’s new DNA sequencing platform.

Antibody drug conjugates are starting to transform cancer treatments, so let’s maintain the momentum.

Biotech companies need good patient samples, but hospitals are not always obliging...

Researchers at Trinity College Dublin explain how they are reaching into the natural environment to source new bioactives.